The Burden of Cardiovascular Disease Attributable to Modifiable Risk Factors and Cost-effectiveness Analysis of IraPEN Program in the General Population of Iran

Mokhtari, Mehdi; Khalil, Davood; Farzadfar, Farshad; Daroudi, Rajabali; Asadi‐Lari, Mohsen

doi:10.47176/mjiri.36.73

Cited by 8 publications

(4 citation statements)

References 38 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While empowering the primary health system has proven effective in controlling hypertension in Iran 49 , and guidelines like IraPen for cardiovascular diseases have demonstrated cost-effectiveness 50 , it would be wise to consider the available resources situation when choosing strategies. Evidence-based approaches, such as those suggested by WHO's "Best Buys" 51 , HEARTS program 52 , follow-ups using text messages 53,54 , and the application of machine learning algorithms 54,55 , should be implemented after thorough cost-effectiveness analyses.…”

Section: Discussionmentioning

confidence: 99%

Trends of Hypertension Stages among Iranian Adults from 2005 to 2025 using WHO STEPS studies: A Comparison among 2017 ACC/AHA, JNC7, and 2020 ISH Guidelines

Golestani,

Sheidaei,

Khosravi

et al. 2024

Preprint

View full text Add to dashboard Cite

Reducing the prevalence of hypertension, a major risk factor with significant health and economic implications is a target outlined by The World Health Assembly. This study investigated the prevalence of hypertension stages in Iran from 2005 to a projection for 2025 by three different guidelines. Eight nationally and sub-nationally representative cross-sectional WHO STEPwise approach to NCD risk factor surveillance (STEPS) studies were conducted from 2005 to 2021 in Iran. Staging followed the Joint National Committee's seventh report (JNC7), the American College of Cardiology/American Heart Association's 2017 guidelines (ACC/AHA), and the International Society of Hypertension's 2020 guidelines (ISH). Using data from a total of 210,546 participants, ACC/AHA projected higher prevalence in stage 1 and stage 2 hypertension, particularly 35–44 and 45–54 age groups of males, each reaching approximately 35% in 2025. Stage 1 hypertension demonstrated a stable trend (about 17%) for ISH and JNC7, whereas ACC/AHA exhibited a significant decrease from 37.07–30.32% between 2005 and 2025. Conversely, all guidelines indicated a significant decreasing trend for stage 2 hypertension from 2005 to 2025 (ACC/AHA: 26.60–23.27%, JNC7 and ISH: about 9–6.6%). The study indicated that the prevalence of hypertension stages has not remarkably changed based on all guidelines in recent years and is projected to remain stable by 2025. The choice of guidelines should consider cost-effectiveness analyses and the available resources.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends of Hypertension Stages among Iranian Adults from 2005 to 2025 using WHO STEPS studies: A Comparison among 2017 ACC/AHA, JNC7, and 2020 ISH Guidelines

Golestani,

Sheidaei,

Khosravi

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…In Iran, the IraPEN program has been launched based on the WHO framework. The cost-effectiveness of the program needs to be evaluated and the program needs to be updated based on diverse trends of CVD risk factors among Iranians [ 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

The contribution of metabolic risk factors to cardiovascular mortality in Golestan cohort study: Population attributable fraction estimation

Gorgani,

Sharafkhah,

Masoudi

et al. 2024

International Journal of Cardiology Cardiovascular Risk and Pre

View full text Add to dashboard Cite

“…More than 30% of fatalities worldwide are caused by coronary heart disease (CHD) (1). CHD is becoming the leading cause of mortality in China due to the country's aging population.…”

Section: Introductionmentioning

confidence: 99%

Relationship between dynamic electrocardiogram and CRP, IL-6, ET-1 expression in myocardial ischemia patients with coronary heart disease

Lin You

2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

The Burden of Cardiovascular Disease Attributable to Modifiable Risk Factors and Cost-effectiveness Analysis of IraPEN Program in the General Population of Iran

Abstract: Estimating the costs associated with disease prevention programs is more important in developing countries. Establishing a cost-effective program to control cardiovascular diseases is essential for any country.

Cited by 8 publications

References 38 publications

Trends of Hypertension Stages among Iranian Adults from 2005 to 2025 using WHO STEPS studies: A Comparison among 2017 ACC/AHA, JNC7, and 2020 ISH Guidelines

Trends of Hypertension Stages among Iranian Adults from 2005 to 2025 using WHO STEPS studies: A Comparison among 2017 ACC/AHA, JNC7, and 2020 ISH Guidelines

The contribution of metabolic risk factors to cardiovascular mortality in Golestan cohort study: Population attributable fraction estimation

Relationship between dynamic electrocardiogram and CRP, IL-6, ET-1 expression in myocardial ischemia patients with coronary heart disease

Contact Info

Product

Resources

About